Case Report: Infectious prophylaxis in hematological malignancies

Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomize...

Descripción completa

Detalles Bibliográficos
Autores principales: Passucci, Mauro, Masucci, Chiara, Paoletti, Francesca, Ielo, Claudia, Costa, Alessandro, Carmosino, Ida, Scalzulli, Emilia, Martelli, Maurizio, Gentile, Giuseppe, Breccia, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183604/
https://www.ncbi.nlm.nih.gov/pubmed/37197426
http://dx.doi.org/10.3389/fonc.2023.1163175
Descripción
Sumario:Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomized data are available to strongly recommend HBV prophylaxis in these patients. Here, we report a case of primary myelofibrosis and past serological evidence of HBV infection, treated with ruxolitinib and concomitant lamivudine, developing HBV reactivation due to premature withdrawal of prophylaxis. This case underlines the potential need for persistent HBV prophylaxis in the setting of ruxolitinib treatment.

Ejemplares similares